Last reviewed · How we verify
H-Bupivacaine
H-Bupivacaine, marketed by Pontificia Universidad Catolica de Chile, is an established product in the local anesthetic market. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue stability. The primary risk lies in the lack of disclosed primary trial results and competitors, which may impact market confidence and positioning.
At a glance
| Generic name | H-Bupivacaine |
|---|---|
| Also known as | Hyperbaric bupivacaine |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Parascapular Sub Iliocostalis Plane Block Versus Thoracic Paravertebral Plane Block for Traumatic Multiple Rib Fractures (NA)
- Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery (NA)
- Postoperative Pain Monitoring With ANI in Lumbar Spine Surgery (NA)
- Perioperative Multimodal Analgesia for Supratentorial Craniotomy (NA)
- Observational Retrospective Study on Spinal Analgesia in Laparoscopic and Laparotomic Hysterectomy
- Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy (NA)
- Intrathecal Morphine for Recovery and Outcomes After VATS (NA)
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H-Bupivacaine CI brief — competitive landscape report
- H-Bupivacaine updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI